RT @Aquarius3_0: @KathMLee1 Yup. JAK inhibitors, also used for atopic eczema (!), is highly effective against C19!!! Says Cochrane...😳 On b…
RT @Aquarius3_0: @KathMLee1 Yup. JAK inhibitors, also used for atopic eczema (!), is highly effective against C19!!! Says Cochrane...😳 On b…
@KathMLee1 Yup. JAK inhibitors, also used for atopic eczema (!), is highly effective against C19!!! Says Cochrane...😳 On board with the author team: Miriam Stegemann, panel member/clinical chair for the WHO "Living Guidelines"...https://t.co/VkDKKkeBKI.
@rubyslippahs Talking about this study, but this really needs more science, as they mention! https://t.co/va7CWbFqAA)%2C%20and
RT @baypropolis: Hastaneye yatan, klinik durumu kötü seyreden #COVID19 hastalarının tedavisinde janus kinaz (JAK) inhibitörleri faydalı gör…
Hastaneye yatan, klinik durumu kötü seyreden #COVID19 hastalarının tedavisinde janus kinaz (JAK) inhibitörleri faydalı görünüyor. Enfekte kişilerin klinik durumunun iyileştirilmesi için ~60 güne kadar yüksek etkinlik sergiliyor. Antiviral özelliği var. ht
RT @CochraneNursing: 🦠 How effective are systemic Janus kinase (JAK) inhibitors for treating #COVID19? 👩⚕️ There are six studies included…
RT @CochraneNursing: 🦠 How effective are systemic Janus kinase (JAK) inhibitors for treating #COVID19? 👩⚕️ There are six studies included…
RT @CochraneNursing: 🦠 How effective are systemic Janus kinase (JAK) inhibitors for treating #COVID19? 👩⚕️ There are six studies included…
RT @CochraneNursing: 🦠 How effective are systemic Janus kinase (JAK) inhibitors for treating #COVID19? 👩⚕️ There are six studies included…
🦠 How effective are systemic Janus kinase (JAK) inhibitors for treating #COVID19? 👩⚕️ There are six studies included in a new #CochraneReview 📌https://t.co/briqJiJSrh @CochraneLibrary @CochraneNursing #CochraneHongKong #cuhknursing #EvidenceforNursing #Co
RT @CochraneJapan: 全身投与のヤヌスキナーゼ阻害剤は、COVID-19の患者にとって有効な治療法か? https://t.co/iBJSgbyLoS
全身投与のヤヌスキナーゼ阻害剤は、COVID-19の患者にとって有効な治療法か? https://t.co/iBJSgbyLoS
Les inhibiteurs systémiques de la janus kinase, aux propriétés antivirales et anti‐inflammatoires potentielles, sont-ils un traitement efficace pour les personnes atteintes de #COVID19 ? @CochraneHaem #RevSyst examine les preuves de 6 études. Résumé FR: h
📣 @cochranecollab, inhibidores de JAK & #COVID19 ·Datos más robustos en baricitinib ·Más estudios en marcha que pueden cambiar los datos ·No queda claro impacto sobre necesidad de VMI o mejoría clínica ·Interesantes comentarios sobre estudio de RECOVE
RT @CochraneLibrary: Are systemic Janus kinase inhibitors, with potential antiviral & anti‐inflammatory properties, an effective treatment…
RT @CochraneLibrary: What are the effects of janus kinase (JAK) inhibitors for people with moderate to severe #COVID19? 📃 Read the new @Co…
RT @ABsteward: 🆕⚡⚡Cochrane review 6 RCTs n=~11k In hospitalised individuals with moderate to severe COVID‐19, moderate‐certainty evidence s…
RT @ABsteward: Based on low‐certainty evidence, JAK inhibitors may make little or no difference in the rate of secondary infection. Subgrou…
RT @ABsteward: Systemic Janus kinase (JAK) inhibitors probably decrease all‐cause mortality of hospitalised people with #COVID19 with a num…
RT @ABsteward: 🆕⚡⚡Cochrane review 6 RCTs n=~11k In hospitalised individuals with moderate to severe COVID‐19, moderate‐certainty evidence s…
RT @ABsteward: 🆕⚡⚡Cochrane review 6 RCTs n=~11k In hospitalised individuals with moderate to severe COVID‐19, moderate‐certainty evidence s…
RT @ABsteward: 🆕⚡⚡Cochrane review 6 RCTs n=~11k In hospitalised individuals with moderate to severe COVID‐19, moderate‐certainty evidence s…
RT @ABsteward: Future studies also need to include outpatients with #COVID19 🤔 This is important : there is a particular lack of studies on…
RT @ABsteward: Bari Vs Toci, more clues #IDTwitter #medtwitter #TwitteRx #MedEd
RT @ABsteward: 🆕⚡⚡Cochrane review 6 RCTs n=~11k In hospitalised individuals with moderate to severe COVID‐19, moderate‐certainty evidence s…
RT @ABsteward: 🆕⚡⚡Cochrane review 6 RCTs n=~11k In hospitalised individuals with moderate to severe COVID‐19, moderate‐certainty evidence s…
RT @ABsteward: 🆕⚡⚡Cochrane review 6 RCTs n=~11k In hospitalised individuals with moderate to severe COVID‐19, moderate‐certainty evidence s…
RT @ABsteward: Bari Vs Toci, more clues #IDTwitter #medtwitter #TwitteRx #MedEd
RT @ABsteward: Systemic Janus kinase (JAK) inhibitors probably decrease all‐cause mortality of hospitalised people with #COVID19 with a num…
RT @ABsteward: 🆕⚡⚡Cochrane review 6 RCTs n=~11k In hospitalised individuals with moderate to severe COVID‐19, moderate‐certainty evidence s…
COVID-19治療におけるJAK阻害薬の違い - コクランレビュー - 全てのJAK阻害薬が中等度以上の28日後死亡リスクを低下 RR 0.72 (0.57-0.91) - 有害事象および二次感染の発生に違いなし - バリシチニブが最も使われていた
RT @ABsteward: 🆕⚡⚡Cochrane review 6 RCTs n=~11k In hospitalised individuals with moderate to severe COVID‐19, moderate‐certainty evidence s…
RT @ABsteward: 🆕⚡⚡Cochrane review 6 RCTs n=~11k In hospitalised individuals with moderate to severe COVID‐19, moderate‐certainty evidence s…
RT @ABsteward: 🆕⚡⚡Cochrane review 6 RCTs n=~11k In hospitalised individuals with moderate to severe COVID‐19, moderate‐certainty evidence s…
RT @ABsteward: 🆕⚡⚡Cochrane review 6 RCTs n=~11k In hospitalised individuals with moderate to severe COVID‐19, moderate‐certainty evidence s…
RT @ABsteward: 🆕⚡⚡Cochrane review 6 RCTs n=~11k In hospitalised individuals with moderate to severe COVID‐19, moderate‐certainty evidence s…
Cochrane review ・バリシチニブ for moderate to severe COVID-19 ・28日までの全死亡を低下させる ・NNT=28 Janus kinase inhibitors for the treatment of COVID‐19 - Kramer, A - 2022 | Cochrane Library https://t.co/MOmq71q4sA
RT @ABsteward: Bari Vs Toci, more clues #IDTwitter #medtwitter #TwitteRx #MedEd https://t.co/qKbkfGNOP7
RT @ABsteward: Future studies also need to include outpatients with #COVID19 🤔 This is important : there is a particular lack of studies on…
RT @ABsteward: Systemic Janus kinase (JAK) inhibitors probably decrease all‐cause mortality of hospitalised people with #COVID19 with a num…
RT @ABsteward: Based on low‐certainty evidence, JAK inhibitors may make little or no difference in the rate of secondary infection. Subgrou…
Bari Vs Toci, more clues #IDTwitter #medtwitter #TwitteRx #MedEd
Future studies also need to include outpatients with #COVID19 🤔 This is important : there is a particular lack of studies on combination or sequence of immunomodulatory treatments against #COVID19 #IDTwitter #MedEd #TwitteRx
Janus kinase inhibitors for the treatment of COVID‐19 - Kramer, A - 2022 | Cochrane Library https://t.co/Xkd3vO44ke
Systemic Janus kinase (JAK) inhibitors probably decrease all‐cause mortality of hospitalised people with #COVID19 with a number needed to treat (NNT) for an additional beneficial outcome of 28. That's great, compared to tocilizumab 🤔 #IDtwitter
Based on low‐certainty evidence, JAK inhibitors may make little or no difference in the rate of secondary infection. Subgroup analysis by severity of COVID‐19 or type of agent failed to identify specific subgroups which benefit more or less from systemic J
RT @ABsteward: Four studies investigated the single agent baricitinib (10,815 participants), one tofacitinib (289 participants), and one ru…
Four studies investigated the single agent baricitinib (10,815 participants), one tofacitinib (289 participants), and one ruxolitinib (41 participants #IDTwitter #medtwitter #TwitteRx #MedEd
RT @ABsteward: Wow, really #IDTwitter https://t.co/qKbkfGwdXz
Wow, really #IDTwitter
🆕⚡⚡Cochrane review 6 RCTs n=~11k In hospitalised individuals with moderate to severe COVID‐19, moderate‐certainty evidence shows that systemic JAK inhibitors probably decrease all‐cause mortality. Baricitinib was the most often evaluated JAK(-) NNT = 28 ht
RT @CochraneIberoam: Los inhibidores de la cinasa Jano han despertado interés como posible tratamiento para la infección por el SARS‐CoV‐2.…
RT @CochraneIberoam: Los inhibidores de la cinasa Jano han despertado interés como posible tratamiento para la infección por el SARS‐CoV‐2.…
Janus kinase inhibitors for the treatment of COVID‐19 https://t.co/8RYiQzRKJj
Los inhibidores de la cinasa Jano han despertado interés como posible tratamiento para la infección por el SARS‐CoV‐2. Una nueva revisión @CochraneLibrary @CochraneHaem concluye que pueden ⬇ la mortalidad por todas las causas en pacientes hospitalizados
RT @CochraneLibrary: What are the effects of janus kinase (JAK) inhibitors for people with moderate to severe #COVID19? 📃 Read the new @Co…
What are the effects of janus kinase (JAK) inhibitors for people with moderate to severe #COVID19? 📃 Read the new @CochraneLibrary Clinical Answer: https://t.co/nx0H5qvyBz 📚 Based on the @CochraneHaem #systematicreview: https://t.co/nPyHTiGXVr #CochraneC
Janus kinase inhibitors for the treatment of COVID‐19 Cochrane meta-analysis: moderate‐certainty evidence shows that systemic JAK inhibitors probably decrease all‐cause mortality; but make little or no difference in improvement in clinical status. https:
ICYMI (like me): there's a Cochrane review now for Jakinibs in COVID Janus kinase inhibitors for the treatment of COVID‐19 - Kramer, A - 2022 | Cochrane Library https://t.co/4ocezh7gFV
Janus kinase inhibitors for the treatment of COVID‐19 Via @CochraneLibrary https://t.co/uyYmiDkjXM
RT @CarlosJMoreno_: NEW #Cochrane Database of Systematic Reviews Inhibidores Janus kinase (JAK) como tratamiento para #COVID19 moderado-sev…
RT @CarlosJMoreno_: NEW #Cochrane Database of Systematic Reviews Inhibidores Janus kinase (JAK) como tratamiento para #COVID19 moderado-sev…
RT @CarlosJMoreno_: NEW #Cochrane Database of Systematic Reviews Inhibidores Janus kinase (JAK) como tratamiento para #COVID19 moderado-sev…
NEW #Cochrane Database of Systematic Reviews Inhibidores Janus kinase (JAK) como tratamiento para #COVID19 moderado-severo. https://t.co/mTtZsAptyR @CochraneIberoam @CochraneMexico https://t.co/j4BpFXdk3Y
New Cochrane review: Are systemic Janus kinase inhibitors an effective treatment for people with COVID-19? https://t.co/NN5oc0Zld4 https://t.co/QVvhI4Kjzs
Are systemic Janus kinase inhibitors an effective treatment for people with COVID-19? https://t.co/5ZLksClePy
Are systemic Janus kinase inhibitors, with potential antiviral & anti‐inflammatory properties, an effective treatment for people with #COVID19? New @CochraneHaem #systematicreview looks at evidence from 6 studies (with 11,145 #COVID patients) to find o
Janus kinase inhibitors for the treatment of COVID-19 https://t.co/KQPbjgy7m0
"We found moderate‐ to high‐certainty evidence from 6 studies to conclude that systemic JAK inhibitors are an effective treatment for COVID‐19 in hospitalised people, because they resulted in fewer deaths and a lower rate of clinical deterioration." https
Are systemic Janus kinase inhibitors an effective treatment for people with COVID-19? | Cochrane https://t.co/XlrEIq2pJ1
Janus kinase inhibitors for the treatment of COVID‐19 - Kramer, A - 2022 | Cochrane Library https://t.co/KASlxmqB7G https://t.co/ihig1Drp7U